piqray 50 mg
novartis israel ltd - alpelisib - film coated tablets - alpelisib 50 mg - alpelisib - piqray is indicated in combination with fulvestrant for the treatment of postmenopausal women, and men, with hormone receptor (hr)-positive, human epidermal growth factor receptor 2 (her2)-negative, pik3camutated, advanced or metastatic breast cancer following progression on or after an endocrine-based regimen
beovu 120 mgml
novartis israel ltd - brolucizumab - solution for injection - brolucizumab 120 mg / 1 ml - brolucizumab - beovu is indicated in adults for the treatment of neovascular (wet) age-related macular degeneration (amd).
bonspri 20mg0.4ml solution for injection in pre-filled syringe
novartis corporation (malaysia) sdn. bhd. - ofatumumab -
adakveo 10 mgml
novartis israel ltd - crizanlizumab - concentrate for solution for infusion - crizanlizumab 10 mg/ml - crizanlizumab - adakveo is indicated to reduce the frequency of vasoocclusive crises (vocs) in adults and pediatric patients aged 16 years and older with sickle cell disease.
cosentyx 300mg2ml solution for injection in pre-filled syringe
novartis corporation (malaysia) sdn. bhd. - secukinumab -
fraizeron 300mg2ml solution for injection in pre-filled pen
novartis corporation (malaysia) sdn. bhd. - secukinumab -
scemblix 20 mg
novartis israel ltd - asciminib as hydrochloride - film coated tablets - asciminib as hydrochloride 20 mg - asciminib - scemblix is indicated for the treatment of adult patients with:• philadelphia chromosome-positive chronic myeloid leukemia (ph+ cml) in chronic phase (cp), previously treated with two or more tyrosine kinase inhibitors (tkis).• ph+ cml in cp with the t315i mutation
scemblix 40 mg
novartis israel ltd - asciminib as hydrochloride - film coated tablets - asciminib as hydrochloride 40 mg - asciminib - scemblix is indicated for the treatment of adult patients with:• philadelphia chromosome-positive chronic myeloid leukemia (ph+ cml) in chronic phase (cp), previously treated with two or more tyrosine kinase inhibitors (tkis).• ph+ cml in cp with the t315i mutation
potassium-novartis tablet (effervescent)
novartis pharmaceuticals canada inc - potassium chloride; potassium bicarbonate - tablet (effervescent) - 600mg; 400mg - potassium chloride 600mg; potassium bicarbonate 400mg - replacement preparations
novartis vaccines & diagnostics pty ltd - procleix ultrio plus assay
novartis vaccines & diagnostics pty ltd -